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Abstract Numerous studies have demonstrated the occur-
rence of pharmaceuticals in the natural environment, raising
concerns about their impact on non-target organisms or hu-
man health. One region where little is known about the expo-
sure and effects of pharmaceuticals in the environment is Iraq.
Due to the high number of pharmaceuticals used by the public
health sector in Iraq (hospitals and care centres) and distribut-
ed over the counter, there is a need for a systematic approach
for identifying substances that should be monitored in the
environment in Iraq and assessed in terms of environmental
risk. In this study, a risk-based prioritization approach was
applied to 99 of the most dispensed pharmaceuticals in three
Iraqi cities, Baghdad, Mosul and Basrah. Initially, information
on the amounts of pharmaceuticals used in Iraq was obtained.
The top used medicines were found to be paracetamol, amox-
icillin and metformin with total annual consumption exceed-
ing 1000 tonnes per year. Predicted environmental concentra-
tions (PECs) and predicted no-effect concentrations (PNECs),
derived from ecotoxicological end-points and effects related
to the therapeutic mode of action, were then used to rank the
pharmaceuticals in terms of risks to different environmental
compartments. Active pharmaceutical ingredients used as an-
tibiotics, antidepressants and analgesics were identified as the
highest priority in surface water, sediment and the terrestrial
environment. Antibiotics were also prioritized according to
their susceptibility to kill or inhibit the growth of bacteria or
to accelerate the evolution and dissemination of antibiotic-
resistant genes in water. Future workwill focus on understand-
ing the occurrence, fate and effects of some of highly priori-
tized substances in the environment.
Key words Pharmaceuticals . Prioritization . Ecotoxicity .
Antibiotic resistance . Risk characterization ratio
Introduction
It is estimated that more than 1500 active pharmaceutical in-
gredients (APIs) are currently in use. Following use, these
compounds can be emitted into the natural environment e.g.
via wastewater collection and treatment networks (Boxall
et al. 2012; Ginebreda et al. 2010). The ongoing use of many
of these APIs by society means that the active substances and
their major metabolites will occur in the environment contin-
uously (Monteiro and Boxall 2010).
For most pharmaceuticals in use, the evidence that they
have deleterious effects on the natural environment is still
limited and our knowledge of the fate of these pharmaceuti-
cals in the environment is still deficient (Roos et al. 2012).
This is partly due to the fact that the number of APIs in use is
large and that experimental data on the environmental levels,
fate and effects are available for only a small proportion of
these substances. For example, the knowledge of environmen-
tal exposure to antibiotics which may lead to possible evolu-
tion and dissemination of antibiotic-resistant pathogens in
bacteria is limited (Bengtsson-Palme and Larsson 2016). To
experimentally assess the environmental risk of all APIs in use
would be a challenge (Perazzolo et al. 2010). One solution is
to use formalized prioritization procedures that identify those
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substances in use that pose the greatest risks towards the nat-
ural environment (Boxall et al. 2012). By using these ap-
proaches, experimental testing resources can then be focused
on those substances that are likely to have the greatest impact.
Several studies have been recently performed that employ
different approaches for ranking and assessing the risk posed
by APIs to the environment. Most have focused on surface or
drinking water and the risks to aquatic organisms or human
health. These approaches have been applied in Switzerland
(Perazzolo et al. 2010), USA (Kostich and Lazorchak 2008;
Dong et al. 2013), France (Besse and Garric 2008), the UK
(Boxall et al. 2003; Guo et al. 2016), South Korea (Kim et al.
2008) and Sweden (Roos et al. 2012). Many of these ap-
proaches use exposure and toxicological predictions so they
can be readily applied to large numbers of compounds with
limited data (Boxall et al. 2012).
Most prioritization studies have focused on North America
and Western Europe, so our knowledge of priorities in other
geographical areas such as Eastern Europe, Africa, Asia and
South America is limited. This can be partly explained by the
challenges in obtaining information on API usage in these
regions. Moreover, although there are strong incentives to
introduce the evaluation of an antibiotic to select for resistance
into environmental risk assessment guidelines (Bengtsson-
Palme and Larsson 2016), none of the previous prioritization
approaches has attempted to assess the risk of antibiotics in the
environment in terms of their potential to select for antimicro-
bial resistance.
In Iraq, there are no specific management guidelines for
pharmaceuticals in the environment. Pharmaceuticals are free-
ly available to everyone without any restriction and regulation
or even without prescription, and there are many routes by
which these substances are distributed to the population.
One route is the public health sector which is represented by
the Ministry of Health (MOH) via the state company for im-
portation and distribution of drug and medical appliances
(KIMADIA). The second source is the private sector (licensed
and unlicensed low value manufacturers) which includes 23
manufacturing plants, importers and dispensers who supply
the local markets with unknown quantities of pharmaceuticals.
Additionally, all the locally produced and imported finished
pharmaceuticals are not subjected to taxes in order to make
them affordable for most of the population (USAID; 2007;
EMRO WHO 2011; MOH 2011).
With a highly urbanized population, Iraq still has insuffi-
cient environmental management and suffers from poor and
old water distribution systems and contaminated main water
resources (UNEP 2003). Due to the absence of water quality
regulations and the continuous discharges from industry and
households via insufficient wastewater treatment plants
(WWTPs), up to 19 % of the Iraqi population is exposed to
unsafe water (UNEP 2003; USAID 2007). In addition, only
32 % of the population is served with wastewater treatment,
meaning that a significant amount of untreated wastewater is
released to the environment (COSIT 2012). Few studies to
evaluate the quality of environmental systems in Iraq have
been performed, and most that have been performed have
focused on monitoring the occurrence of trace metals, poly-
cyclic aromatic hydrocarbons (PAHs) and non-polar lipids in
the aquatic environment (Abaychi and DouAbul 1985; Al-
Saad 1987; Rushdi et al. 2014). The risks of emerging con-
taminants such as pharmaceuticals have been neglected.
The aim of the present study was therefore to establish the
importance of API exposure as a pressure on the natural envi-
ronment in Iraq and to identify APIs of most concern in local
aquatic and terrestrial environments of the three main cities in
the country (Baghdad, Mosul and Basrah), where only little is
currently known about the exposure and effects of these sub-
stances. The prioritization approaches used to achieve this
were based on the potential for APIs to enter the aquatic and
terrestrial environments and their potential toxic effects on the
ecosystems, bacterial community and human health.
Materials and methods
Prioritization approach
The prioritization approach is illustrated in Fig. 1 and involved
the use of predicted environmental concentrations (PECs) and
concentrations relating to different effect endpoints (i.e. pre-
dicted no-effect concentrations (PNECs), human plasma ther-
apeutic concentrations (HTPCs), minimal inhibitory concen-
trations (MICs) and minimal selective concentrations
(MSCs)) for each of the pharmaceuticals in aquatic and terres-
trial systems. PECs and PNECs were then used to calculate
risk characterization ratios (RCRs) for apical endpoints, sec-
ondary poisoning, toxicity to humans and antimicrobial resis-
tance selection. Pharmaceuticals were then ranked based on
their RCRs where compounds with the highest RCRs were
considered the highest priority.
Data collection
Usage data
Data on the consumption of pharmaceuticals for hospitals and
primary care centres in Iraq in 2014were obtained from the state
companyKIMADIA (Kimadia, access 2014). To obtain the total
amount of pharmaceuticals consumed, concentrations of active
ingredient in packaging units (i.e. blister, bottle, etc.) were con-
verted into mass units. Vitamins, medical supplements, electro-
lytes and vaccines were excluded which reduced the list of APIs
to 99 compounds. In the case of combined medicines, only
individual active ingredients were considered and summed up
to calculate the weight of pharmaceutical compound.
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Information is scarce on the use of over-the-counter phar-
maceuticals in Iraq. However, research by the Center of
Market Research and Consumer Protection at the University
of Baghdad (Mohammed et al. 2009) indicates that over-the-
counter usage can contribute 68 % of the total usage of phar-
maceuticals in Iraq. Therefore, to obtain a total pharmaceutical
usage in Iraq (for both hospitals and primary care centres and
over the counter), the results of the analysis of the KIMADIA
data were multiplied by a factor of 3.125. Some APIs, such as
cancer treatments or those used in surgical procedures in
hospitals, were not corrected (multiplied by the factor) as they
would not be distributed over the counter. The final usage data
are provided in the supporting information (Table S1).
Effects data and physico-chemical properties
To estimate the environmental risk posed by the pharmaceuticals
to aquatic and terrestrial ecosystems in Iraq, data on toxicity of
the APIs to algae, daphnia, fish and earthworms was used. The
data collection included acute and chronic ecotoxicity endpoints
Fig. 1 The developments of prioritization approach of pharmaceuticals
in the environment in Iraq. RCR risk characterization ratios, PECsw,
PNECsw predicted environmental concentration and predicted no-effect
concentration in surface water, PECsludge predicted environmental
concentration in sludge compartment, PECsed, PNECsed predicted
environmental concentration and predicted no-effect concentration in
sediment compartment, WWTPwastewater treatment plant, BCF fish
bioconcentration factor, BMF biomagnification factor, PECbiota
predicted environmental concentration in biota (e.g. fish), PNEChuman
predicted no-effect concentration in humans from drinking water and
fishery products consumption, PECsoil predicted environmental
concentration in soil, FSSPC fish steady state plasma concentration,
HTPC human therapeutic plasma concentration, PECwarthworm
predicted environmental concentration in earthworm, PNECearthworm
predicted no-effect concentration in earthworm, PNECmammal predicted
no effect concentration in mammal, MIC minimal inhibitory
concentration, PNECresistance predicted no-effect concentration for
antibiotics resistance selection, MSC minimal selective concentration
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(typically the most sensitive LC/EC50 value). These data were
obtained from the peer-reviewed literature, grey literature and
available online databases (e.g. Swedish voluntary environmen-
tal classification of pharmaceuticals at www.fass.se). As
experimental ecotoxicity data were not available for a large
number of the pharmaceuticals, estimation tools, such as
Quantitative Structure-Property Relationships (QSAR) used in
the Organisation for Economic Co-operation and Development
(OECD QSAR, 2013) Toolbox and the Ecological Structure
Activity Relationship ECOSAR (USEPI 4.1) software, were
used to fill data gaps (Guo et al. 2016). The database present in
the QSAR Toolbox was used to identify experimental data for
molecules deemed ‘similar’ to each of the individual pharmaceu-
tical with no data. Then, within the software, a relationship was
built to allow an estimation of the ecotoxicological endpoint for
the query molecule. Regarding human and mammalian toxicity
effects from oral exposure, endpoints such as acceptable daily
intake (ADI) values and median lethal dose (LD50) for
rat/mouse were used (Technical Guidance for Deriving
Environmental Quality Standards EC 2011, Carvalho et al.
2015; Guo et al. 2016). The HTPCs available in peer-
reviewed publications were used in the fish plasma model.
Finally, for terrestrial toxicity, earthworm acute toxicity (14-
day LC50 in mM kg−1 dry soil) was predicted using the
QSAR available in ECOSAR for compounds with no exper-
imentally determined earthworm ecotoxicity data. Due to the
absence of experimentally determined effects of antibiotics in
complex microbial communities, the theoretical MICs, MSCs
and PNECs selective resistance calculated by Bengtsson-
Palme and Larsson (2016) were used.
Physico-chemical properties required for predicting the fate
and behavior of pharmaceuticals in the environment were
collated from published articles and open resources.
DrugBank, NCCOS (2014) was used to obtain acid dissocia-
tion constants (pKa), and the CODATA (2014) database was
used to obtain octanol-water partition coefficients (Kow). As
there was a lack of experimental data on organic carbon parti-
tion coefficient (Koc) for the APIs, for compounds where
experimental Koc data were not available, we used the estima-
tion model developed by Franco and Trapp (2008). Excretion
profiles for pharmaceuticals were obtained from the
peer-reviewed literature, databases or pharmaceutical safety
data sheets (i.e. MEDSAFE, Pfizer).
Wastewater generation and dilution factor
Information on wastewater disposal for the main highly ur-
banized cities in Iraq (Baghdad, Mosul and Basrah) was col-
lected. The daily generated wastewater discharges are 1.6 mil-
lion m3/day in Baghdad, 0.5 million m3/day in Mosul and
0.331 million m3/day in Basrah (COSIT 2014). These data
were used to calculate the wastewater generated per inhabitant
(Supporting Information, Equation S1).
It is difficult to determine the dilution factor (DF) in coun-
tries with none or very scarce hydrological information like
Iraq. For this purpose, we therefore used two dilution factors
of 10 and 40 which had been estimated based on a national
scale for Iraq by Keller et al. (2014). The percentage of waste-
water treatment efficiency will also be important for the cal-
culation of exposure concentrations in surface water so infor-
mation was also collected on the percentage connectivity to
wastewater treatment plants for the three cities. Data on the
population, wastewater per capita, wastewater treatment per-
centage and dilution factors for the cities under study is pro-
vided in Table S3 in the supporting information.
Exposure assessment
Predicted environmental concentrations of APIs on the usage
list were calculated in aquatic systems (surface water and sed-
iment) and terrestrial systems according to the Guideline on
the Environmental Risk Assessment of Medicinal Products
for Human Use (EMEA 2006) and the Technical Guidance
Document on Risk Assessment part II (TGD 2003) with some
modifications to be fitted to the case of Iraq. In surface water,
PECsw values for APIs were calculated using the following
equation (Eq.1):
PECsw ¼
Subinhab Fexc
WasteWinhab Dilution
 1−
Sludge inhab Koc focsludge
WasteWinhabþ Sludge inhab Koc focsludgeð Þ
 
ð1Þ
where PECSW is the PEC of an API in surface water. Subinhab
is the consumed amount of pharmaceuticals per inhabitant in
Iraq per day (mg/inh/day) and was calculated based on annual
pharmaceutical consumption (kg year−1) and using the popu-
lation of Iraq (34.2 million), (Eq. S2, Supporting Information);
DF is the dilution factor of 10 and 40 andWWinhab is the daily
amount of wastewater per inhabitant in either Baghdad, Mosul
or Basrah. Fexc is the fraction of parent ingredients excreted
unchanged via human metabolism. Sludgeinhab [kg/inh/day] is
the mass of waste sludge per inhabitant per day, which is
0.074 (EC 2001); Koc is the organic carbon partitioning co-
efficient determined experimentally or estimated according to
Franco and Trapp (2008) for ionisable chemicals using Kow
and pKa; and focsludge is the fraction of sludge organic carbon
and was assumed to be 0.326 (Struijs et al. 1991).
The assumption of removal by adsorption was just used in
the case of Baghdad because of the absence of wastewater
treatment in both Mosul and Basrah. For Mosul, there are no
wastewater treatment plants in the city while for Basrah the
efficiency percentage of wastewater treatment in existing
WWTPs is zero (COSIT 2014).
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For sediment, the standard algorithms in the TGDII (2003)
was used to estimate concentrations of the APIs in terms of
wet weight (ww) (PECsed_ww), and since the final PECsed
was calculated in terms of dry weight, a conversion step was
applied to determine PECsed on a dry weight basis (Carvalho
et al. 2015) (Eqs. S2 to S5 in Supporting Information).
For the calculation of the PECbiota, the following equation
was used.
PECbiota ¼ PECsw  BCFbiota BMF ð2Þ
where BCF is the bioconcentration factor for biota (e.g. fish)
which was retrieved when available or calculated according to
Fick et al. (2010) (Eq. S7, Supporting Information). Default
biomagnification factor (BMF) values were retrieved from
technical guidance document (EC 2001).
Data on measured levels of pharmaceuticals in fish plasma
following exposure via water are still scarce (Fick et al. 2010).
As an indicator of specific drugs’ potential to cause adverse
pharmacological effects at certain concentrations, the fish
steady state plasma concentration (FSSPC) resulting from ex-
posure via surface water was calculated (Eq. S8 in Supporting
Information). Predictions were based on estimations of the
partitioning of an API between the aqueous phase and arterial
blood in the fish (Pblood/water) (Eqs. S9 and S10 in
Supporting Information). This partition coefficient was initial-
ly estimated based on the log KOW of the API, and this was
subsequently combined with the PECsw to estimate the
FSSPC.
PECsoil was calculated since a PECsludge had been
calculated using algorithms described in the TGD (2003). To
estimate the concentration of an API in earthworms
(PECearthworm), the concentration in the earthworms on a
wet weight basis (C earthworm) was calculated using an esti-
mate of the concentration in porewater (Cporewater) from
PECsoil by considering the partitioning behaviour of sub-
stances between the soil and aqueous phase (Eqs. S11 to
S13 in Supporting Information). The BCF for earthworms
was calculated according to the approach in the TGD (2003).
Hazard characterization
In order to calculate PNECs for toxicity to surface water or-
ganisms, effects data were divided by a relevant assessment
factor (AF), i.e. acute QSAR data =1000; acute experimental
data =100; chronic QSAR data =100 and chronic experimen-
tal data =10, (TGD 2003). In instances where more than one
ecotoxicological value was found, the most sensitive endpoint
was used for the generation of the PNEC. PNECs for earth-
worms were obtained by dividing the 14-day LC50 value by
an AF of 1000. PNECs for mammals were obtained by divid-
ing median lethal doses for mouse or rat by an AF of 100.
PNECs for resistance were obtained from MSCs using an AF
of 10. AFs were not used for the estimation of concentrations
causing mode of action-based effects (using the HTPC) or for
the MICs for microbes. Specific equations are provided in the
Supporting Information (Eqs. S9–S11).
Results and discussion
Experimental data availability
Experimental acute ecotoxicological data were only available
for 51 of the 99APIs under consideration. Chronic ecotoxicity
endpoints were only available for 21 compounds so the
ecotoxicity values of the others were estimated using
the QSAR Toolbox and the ECOSAR software. In terms
of data on mammalian safety, data were available on the
toxicity of 72 compounds, 87 had an ADI and 88 had a
HTPC. Experimental bioconcentration factors in fish
(BCFfish) were only available for two compounds
(diclofenac and naproxen). Experimental organic carbon par-
tition coefficient (Koc) values were only available for 21 phar-
maceuticals (Table 1).
RCR lists of APIs in different systems
The top ranked APIs with RCR >0.1, derived from the differ-
ent prioritizations for the aquatic environments in the three
cities under consideration and at two dilution factors, are pre-
sented in Tables 2 and 3 for surface water and Table 4 for
sediment. The compounds on the top of the prioritization list
with an RCR ≥1 according to PECsw and acute
Table 1 Summary of experimental data available for the APIs
under consideration
Parameter Number of
compounds
Excretion profile (Fex) 81
Log Kow 90
pKa 94
Experimental Koc 21
Experimental endpoint (acute LC(EC) 50) 51
Experimental endpoint (chronic LC(EC) 50) 21
Experimental Bioconcentration factor in fish 2
Acceptable daily intake (ADI) 87
Mammalian toxicity (LD50) for rat/mouse 72
Human therapeutic plasma concentration (HTPC) 88
Fex fraction of parent ingredients excreted unchanged via human metab-
olism, log Kow octanol-water partitioning coefficient, pKa dissociation
coefficient,Koc organic carbon partition coefficient, EC50 50% effective
concentration, LC50 50 % lethal concentration, LD50median lethal dose
for rat/mouse, BCF bioconcentration factor in fish, ADI acceptable daily
intake, HTPC human therapeutic plasma concentration
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Table 2 Top ranked APIs with RCR >0.1 from each prioritization approach for exposure via surface water at D = 10
Location RCR Low level trophic Subtle effects on
fish
Mammalian
predator
Human (uptake
from fishery
products)
Human (uptake
from drinking
water)
Effect of antibiotics on bacteria
Acute aquatic Chronic aquatic FSSPC: HTPC PECFISH: PNEC
mammal
PECFISH:
PNEC biota, hh
PECSW:
PNEC dw, hh
PECSW: MIC PECSW: MSC PEC SW: PNEC
resistance selection(PECSW: acute
PNEC aquatic)
(PECSW: chronic
PNEC aquatic)
D10 D10 D10 D10 D10 D10/D40 D10 D10 D10
Baghdad >10 Amoxicillin Clarithromycin Amoxicillin Clarithromycin Phenylephrine
Atorvastatin
Mebeverine
Mefenamic acid
Phenylephrine Phenylephrine Amoxicillin Metronidazole
1–≤10 Azithromycin
Valproic acid Paracetamol
Diclofenac Miconazole
nitrate Mefenamic acid
Mefenamic acid
Miconazole nitrate
Atorvastatin Amoxicillin Amoxicillin
Ceftriaxone Sodium
Metronidazole
Trimethoprim Ceftriaxone
Sodium Ampicillin
Clarithromycin Cefalexine
0.1–<1 Cefalexine Ciprofloxacin
Miconazole nitrate
Mefenamic acid
Erythromycin Ibuprofen
Erythromycin Paracetamol
Naproxen Azithromycin
Mesalazine Mebeverine
Amitriptyline
Metformin
Miconazole nitrate
Valproic acid Diazepam
Atorvastatin
Mefenamic acid
Valproic acid
Miconazole
nitrare
Ceftriaxone Sodium
Metronidazole
Ampicilline
Clarithromycin
Trimethoprim
Cefalexine
Ampicilline
Ciprofloxacin
Azithromycin
Mosul >10 Amoxicillin Azithromycin Amoxicillin Clarithromycin Phenylephrine
Atorvastatin
Mebeverine
Phenylephrine Phenylephrine Amoxicillin Metronidazole
1–≤10 Ciprofloxacin Valproic acid
Erythromycin Paracetamol
ClarithromycinCefalexine
Erythromycin Diclofenac
Miconazole nitrate
Mefenamic acid
Amitriptyline
Mefenamic acid
Atorvastatin Amoxicillin Amoxicillin
Ceftriaxone Sodium
Metronidazole
Ciprofloxacin Trimethoprim
Ceftriaxone Sodium
Ampicillin Clarithromycin
Cefalexine Erythromycin
0.1–<1 Miconazole nitrate
Mefenamic acid
Ibuprofen Tetracycline
Metronidazole
Trimethoprim
Paracetamol Azithromycin
Naproxen Mesalazine
Mebeverine
Metformin
Miconazole nitrate
Diazepam Atorvastatin
Octreotide
Octreotide Tramadol Ceftriaxone Sodium
Metronidazole
Ciprofloxacin
Ampicillin
Trimethoprim
Ciprofloxacin
Clarithromycin
Trimethoprim
Cefalexine E
ythromycin
Ampicillin
Azithromycin
Basrah >10 Amoxicillin Azithromycin Amoxicillin Clarithromycin
Erythromycin
Phenylephrine
Atorvastatin
Mebeverine
Phenylephrine Phenylephrine Amoxicillin Metronidazole
1–≤10 Ciprofloxacin Valproic acid
Erythromycin Paracetamol
Clarithromycin Cefalexine
Diclofenac Miconazole
nitrate Mefenamic acid
Amitriptyline
Mefenamic acid
Atorvastatin Amoxicillin Amoxicillin
Ceftriaxone Sodium
Metronidazole
Ciprofloxacin Trimethoprim
Ceftriaxone Sodium
Ampicillin Clarithromycin
Cefalexine Erythromycin
0.1–<1 Miconazole nitrate Mefenamic
acid Ibuprofen Tetracycline
Metronidazole
Trimethoprim Atorvastatin
Paracetamol Azithromycin
Naproxen Mesalazine
Mebeverine
Metformin
Miconazole nitrate
Glibenclamide
Diazepam Atorvastatin
Octreotide
Miconazole nitrare
Captopril
Octreotide Captopril Tramadol Ceftriaxone Sodium
Metronidazole
Ciprofloxacin
Ampicillin
Trimethoprim
Erythromycin
Ciprofloxacin
Clarithromycin
Trimethoprim
Cefalexine
Erythromycin
Ampicillin
Azithromycin
PECsw predicted environmental concentration in surface water, FSSPC fish steady-state plasma concentration, HTPC human plasma therapeutic concentration, PECFISH predicted environmental
concentration in fish, PNEC dw predicted no-effect concentrations in drinking water, PNECaquatic/PNECmammal predicted no-effect concentrations in aquatic and mammalian organisms,MICminimal
inhibitory oncentration, MSC minimal selective concentration, PNEC resistance selection predicted no effect concentrations for antimicrobial resistance, D dilution factor
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Table 3 Top ranked APIs with RCR >0.1 from each prioritization approach for exposure via surface water at D = 40
Location RCR Low level trophic Subtle effects on
fish
Mammalian
predator
Human (uptake
from fishery
products)
Human (uptake
from drinking
water)
Effect of antibiotics on bacteria
Acute aquatic Chronic aquatic FSSPC: HTPC PECFISH:
PNEC
mammal
PECFISH:
PNEC biota, hh
(PECSW:
PNEC dw, hh)
PECSW:
MIC
PECSW: MSC PEC SW: PNEC
resistance selection(PECSW: acute PNEC
aquatic)
(PECSW: chronic PNEC
aquatic)
D40 D40 D40 D40 D40 D10/D40 D40 D40 D40
Baghdad >10 Amoxicillin Amoxicillin Phenylephrine Phenylephrine Amoxicillin Metronidazole
1–≤10 Clarithromycin Azithromycin
Valproic acid
Clarithromycin Atorvastatin
Mebeverine
Phenylephrine Amoxicillin Trimethoprim Ceftriaxone
Sodium Ampicillin
Clarithromycin
0.1–<1 Paracetamol Cefalexine
Ciprofloxacin Miconazole
nitrate Mefenamic acid
Diclofenac Miconazole nitrate
Mefenamic acid
Erythromycin Paracetamol
Mefenamic acid
Amitriptyline
Mefenamic acid
Miconazole
nitrate
Atorvastatin Amoxicillin Ceftriaxone Sodium
Metronidazole
Cefalexine Ciprofloxacin
Azithromycin Ciprofloxacin
Mosul >10 Amoxicillin Amoxicillin Phenylephrine Phenylephrine Phenylephrine Amoxicillin Metronidazole
1–≤10 Azithromycin Ciprofloxacin
Valproic acid Erythromycin
Clarithromycin Erythromycin Atorvastatin
Mebeverine
Amoxicillin Ciprofloxacin Trimethoprim
Ceftriaxone Sodium
Ampicillin Clarithromycin
Cefalexine Erythromycin
0.1–<1 Paracetamol Clarithromycin
Cefalexine Miconazole
nitrate Mefenamic acid
Diclofenac Miconazole nitrate
Mefenamic acid Paracetamol
Azithromycin Naproxen
Amitriptyline
Mefenamic acid
Atorvastatin
Octreotide
Tramadol Amoxicillin
Ceftriaxone
Sodium
Ceftriaxone Sodium
Metronidazole
Ciprofloxacin
Azithromycin
Basrah >10 Amoxicillin Amoxicillin Phenylephrine
Atorvastatin
Phenylephrine
HCL
Phenylephrine Amoxicillin
1–≤10 Azithromycin Ciprofloxacin
Valproic acid Erythromycin
Clarithromycin Erythromycin Mebeverine Amoxicillin Amoxicillin M tronidazole Ciprofloxacin
Trimethoprim
0.1–<1 Paracetamol Clarithromycin
Miconazole nitrate
Cefalexine Mefenamic acid
Tetracycline Ibuprofen
Diphenhydramine
Diclofenac Miconazole nitrate
Mefenamic acid Paracetamol
Azithromycin Naproxen
Amitriptyline
Mefenamic acid
Metformin
Diazepam Atorvastatin
Octreotide
Tramadol Ceftriaxone
Sodium
Metronidazole
Ceftriaxone Sodium
Metronidazole
Ciprofloxacin
Ceftriaxone Sodium Ampicillin
Clarithromycin Cefalexine
Erythromycin
Azithromycin
PECsw predicted environmental concentration in surface water, FSSPC fish steady-state plasma concentration, HTPC human plasma therapeutic concentration, PECFISH predicted environmental
concentration in fish, PNEC dw predicted no-effect concentrations in drinking water, PNECaquatic/PNECmammal predicted no-effect concentrations in aquatic and mammalian organisms,MICminimal
inhibitory oncentration, MSC minimal selective concentration, PNEC resistance selection predicted no effect concentrations for antimicrobial resistance, D dilution factor.
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Table 4 Top ranked APIs with RCR >0.1 in the three cities (Baghdad, Mosul, Basrah) according to the predicted concentrations in sediment (PECsed) and at 10 and 40 dilution factors
Baghdad Mosul Basrah
Acute aquatic (PECsed: acute
PNECsed)
Chronic aquatic (PECsed:
chronic PNECsed)
Acute aquatic (PECsed: acute
PNECsed)
Chronic aquatic (PECsed:
chronic PNECsed)
Acute aquatic (PECsed: acute
PNECsed)
Chronic aquatic (PECsed:
chronic PNECsed)
RCR D10 D40 D10 D40 D10 D40 D10 D40 D10 D40 D10 D40
>10 Amoxicillin Amoxicillin
Erythromycin
Azithromycin
Ciprofloxacin
Amoxicillin Amoxicillin
Clarithromycin
Amoxicillin
Erythromycin
Azithromycin
Ciprofloxacin
Amoxicillin
Erythromycin
Amoxicillin
Clarithromycin
Amoxicillin
1-10 Erythromycin
Azithromycin
Valproic acid
Paracetamol
Ciprofloxacin
Amoxicillin
Erythromycin
Azithromycin
Valproic acid
Amoxicillin
Clarithromycin
Diclofenac
Miconazole nitrate
Mefenamic acid
Amoxicillin
Clarithromycin
Valproic acid
Paracetamol
Cefalexin
Azithromycin
Erythromycin
Ciprofloxacin
Valproic acid
Erythromycin
Diclofenac
Miconazole
nitrate
Mefenamic acid
Amoxicillin
Clarithromycin
Erythromycin
Diclofenac
Valproic acid
Paracetamol
Clarithromycin
Azithromycin
Ciprofloxacin
Valproic acid
Erythromycin
Diclofenac
Miconazole
nitrate
Mefenamic acid
Clarithromycin
Erythromycin
0.1–<1 Cefalexine
Miconazole
nitrate
Clarithromycin
Mefenamic
acid Ibuprofen
Metronidazole
Erythromycin
Paracetamo
Ciprofloxacin
Cefalexine
Miconazole
nitrate
Clarithromycin
Mefenamic acid
Paracetamol
Naproxen
Erythromycin
Azithromycin
Mesalazine
Mebeverine
Diclofenac
Miconazole
nitrate
Mefenamic
acidParacetamol
Miconazole nitrate
Clarithromycin
Mefenamic acid
Ibuprofen
Tetracycline
Metronidazole
Trimethoprim
Paracetamol
Cefalexine
Miconazole nitrate
Clarithromycin
Mefenamic acid
Paracetamol
Azithromycin
Naproxen
Mesalazine
Mebeverine
Miconazole nitrate
Mefenamic acid
Paracetamol
Azithromycin
Naproxen
Cefalexine
Miconazole
nitrate
Mefenamic acid
Ibuprofen
Metronidazole
Paracetamol
Clarithromycin
Cefalexine
Miconazole
nitrate
Mefenamic
acid
Paracetamol
Naproxen
Azithromycin
Mesalazine
Mebeverine
Diclofenac
Miconazole
nitrate
Mefenamic acid
Paracetamol
The PECsed and PNECsed were calculated with the equilibrium partitioning method from the PECsw and PNECsw, respectively
PECsed predicted environmental concentration in sediment, PNECsed predicted no effect concentrations in sediment, D dilution factor
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ecotoxicological endpoint were amoxicillin, azithromycin,
cefalexine, valproic acid, erythromycin, paracetamol and
clarithromycin in Mosul and Basrah. In Baghdad, only five
compounds had an RCR ≥1 (amoxicillin, clarithromycin,
azithromycin, valproic acid and paracetamol). This difference
between the cities is due to the absence of wastewater treat-
ment processes inMosul and Basrah and hence that no remov-
al of APIs by adsorption on sludge will occur in these cities.
When chronic effects were considered, at the lower dilution
factor, six compounds had RCR values ≥1 for all cities i.e.
amoxicillin, clarithromycin, diclofenac, miconazole nitrate
and mefenamic acid. At the higher dilution rate, only two
compounds (amoxicillin and clarithromycin) had an RCR ≥1
(Table 3). All other pharmaceuticals had a risk score <0.1
(Table S3, Supporting Information).
When the potential impact of subtle pharmacological ef-
fects were considered by comparing the human therapeutic
concentration in plasma to estimated levels in fish plasma,
using a dilution factor of 10, phenylephrine, atorvastatin and
mebeverine showed RCR values >1 in all three cities.
Additionally, amitriptyline and mefenamic acid had an RCR
≥1 InMosul and Basrah. Using the higher dilution factor, only
phenylephrine showed RCR >1 in Baghdad and Mosul
whereas phenylephrine and atorvastatin exceeded an RCR of
1 in Basrah (Table 3).
Assessment of human exposure from consumption of fish
products showed that phenylephrine and atorvastatin had an
RCR >1 in all cities when a DF of 10 was used and only
phenylephrine (RCR >1) when the DF of 40 was used.
For human exposure via drinking water, tramadol HCL
was the highest ranked compound (with an RCR be-
tween 0.1 and 1 while for the rest of pharmaceuticals
the RCR was below 0.1.
The predicted concentrations for amoxicillin in all cities
when DF=10 was used were close to the MICs, and the
RCRs were between 1 to 10, suggesting that concentration
could be high enough to inhibit growth of or kill bacteria.
Amoxicillin and metronidazole were on the top list of antibi-
otics identified as a risk for selection for bacterial resistance
(RCR >10), with a further seven APIs having RCR values
between 1 and 10 (Tables 2 and 3).
The highest ranked APIs based on acute effect in sediment
organisms were amoxicillin, erythromycin, azithromycin, cip-
rofloxacin, valproic acid and paracetamol in all cities with
RCR >1 (Table 4). Ciprofloxacin was dropped off the top
priority list when a DF of 40 was applied in Mosul and
Basrah and also paracetamol in Baghdad. The highest ranked
compounds based on chronic endpoints were amoxicillin,
clarithromycin, diclofenac, miconazole nitrate and mefenamic
acid at DF=10 and only amoxicillin showed RCR >10 in
Basrah at DF=40.
In soil, theophylline was ranked highest priority based on
the effect on lower trophic level organisms (earthworm).
Based on the potential for secondary poisoning in the aquatic
environment (i.e. risk to mammalian predators), only phenyl-
ephrine had an RCR >1 for all the city scenarios. For second-
ary poisoning in the terrestrial environments (i.e. earthworm-
eating birds and mammals), the highest ranked compoundwas
atropine with an RCR between 0.1 and 1 (Table 5).
Comparison of ranking outcomes
Generally, the outcome of the risk-based prioritization showed
that the majority of the top ranked pharmaceuticals were anti-
biotics. Based on all risk comparisons, a final list of 23 com-
pounds (amoxicillin, amitriptyline, ampicillin, atorvastatin,
azithromycin, cefalexine, ceftriaxone sodium, ciprofloxacin,
clarithromycin, diclofenac, erythromycin, ibuprofen, valproic
acid, mebeverine, mefenamic acid, metronidazole, micona-
zole nitrate, olanzapine, omeprazole paracetamol, phenyleph-
rine, theophylline, trimethoprim) which had an RCR >1 for at
least one endpoint or compartment was generated.
Interestingly, the results of the current prioritization approach
agreed with previously published prioritization studies from
other countries. Amoxicillin, the compound with the highest
score in this study, was also ranked the top veterinary medi-
cine with high hazard to aquatic organisms in the UK and
Korea (Boxall et al. 2003; Kim et al. 2008). Clarithromycin
and azithromycin where found alongside amoxicillin on the
top priority list in France (Besse and Garric 2008).
Paracetamol, amoxicillin and azithromycin were ranked as
highly prescribed pharmaceuticals of concern in the USA
whereas ciprofloxacin was identified as posing a risk toward
aquatic organisms and humans (Dong et al. 2013).
Paracetamol, mefenamic acid, amoxicillin, ciprofloxacin,
erythromycin and valproic acid were prioritized as highest
environmental risk in Switzerland (Perazzolo et al. 2010). A
prioritization study performed by Roos et al. (2012) showed
amitriptyline, paracetamol, diclofenac and valproic acid to be
the highest ranked compounds in one or more comparison
studies in Sweden while no antibiotics from this study were
found in the ranking lists. Paracetamol ranked the 2nd in terms
of usage volume in Sweden while in Iraq it was found to be 1st
on the prioritization list. Diclofenac showed a risk score of
0.013 which is equal to the one reported in the UK by
Ashton et al. (2004). On the other hand, this compound
showed a higher risk score (1–10) in Iraq when chronic eco-
toxicological endpoints were used. A recent risk-based prior-
itization study in the UK has shown most of the antibiotics in
our list (amoxicillin, azithromycin, ciprofloxacin,
clarithromycin and atorvastatin) to have risk scores greater
than 1 in one or more of the risk comparisons proposed
(Guo et al. 2016). Amitriptyline was ranked as high priority
compound when the potential impact of subtle pharmacolog-
ical effects was considered by comparing the HTPC to esti-
mated levels in fish in the same study. Miconazole was ranked
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as one of the priority substances used as herd treatment that is
moderately used and metabolized (Boxall et al. 2003). It was
also found on the top ranking list of pharmaceuticals accord-
ing to the fish plasma model (Roos et al. 2012). Theophylline
showed low risk score in aquatic system, and this agrees with
a ranking score of 0.015 in surface water reported by Huschek
et al. (2004); while in this study the RCR of theophylline
toward terrestrial lower trophic levels was >1 followed by
omeprazole and olanzapine. Omeprazole was ranked 19th
and 22nd in terms of number of prescribed pharmaceuticals
Table 5 Top 20 compounds from
each prioritization approach
considered (Baghdad only),
according to the predicted
concentrations in soil (PECsoil)
RCR Low level trophic Higher trophic levels
Mammalian predator
PECsoil: PNECworm PECearthworm:
PNECmammal
PECearthworm: ADI
>10
1–10 1 Theophylline
2 Omeprazole
3 Olanzapine
0.1–
<1
4 Fluoxetine
5 Atropine sulphate
6 Guaifenesin
7 Ciprofloxacin
8 Phenylephrine
9 Metoprolol
10 Mefenamic acid
11 Octreotide
12 Procyclidine
13 Valproic acid
14 Dextromethorphan
Hydrobromide
15 Pethidine
1 Atropine sulphate
<0.1 16 Diphenhydramine
17 Sitagliptin
18 Flutamide
19 Trifluoperazine
20 Fluovastatin
2 Procyclidine
3 Olanzapine
4 Diazepam
5 Metoclopramide
6 Octreotide
7 Omeprazole
8 Sitagliptin
9 Guaifenesin
10 Dextromethorphan
Hydrobromide
11 Diphenhydramine
12 Metoprolol
13 Ranitidine
14 Chlorphenamine Maleate
15 Ciprofloxacin
16 Theophylline
17 Pseudoephedrine
18 Pethidine
19 Neostigmine
20 Escitalopram oxalate
1 Atropine sulphate
2 Olanzapine
3 Omeprazole
4 Octreotide
5 Procyclidine
6 Metoprolol
7 Escitalopram oxalate
8 Sitagliptin
9 Thyroxine sodium
10 Ranitidine
11 Guaifenesin
12 Dextromethorphan
Hydrobromide
13 Trifluoperazine
14 Ketotifen
15 Letrozole
16 Midazolam
17 Metoclopramide
18 Infliximab
19 Pseudoephedrine
20 Bromhexine
PECsoil, PECearthworm predicted environmental concentrations in in soil and earthworm, ADI acceptable daily
intake, PNECmammal, PNECworm predicted no-effect concentrations in mammals and in worm
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in the prioritization studies in the USA and Sweden (Dong et
al. 2013; Roos et al. 2012). No previous prioritization study
has ranked phenylephrine as a compound of concern. To our
knowledge and after reviewing the literature, antibiotics have
not been previously prioritized in surface water in terms of
their impact on bacterial community or the susceptibility to
pose bacterial resistance.
Pharmaceuticals of concern on the top of priority lists
Antibiotics are often ranked as the highest priority compounds
in risk characterization exercises. Recently, the awareness of
the risks of antibiotics in the environment has been raised. For
example, the European Environmental Quality Directive has
added four antibiotics to the watch list of the Water
Framework Directive (Carvalho et al. 2015). All of the added
antibiotics (azithromycin, erythromycin, ciprofloxacin and
clarithromycin) are ranked as high risk compounds in our
priority list. Antibiotics are structurally diverse and do not
share a common mode of action (Sanderson et al. 2004), and
very low concentrations of antibiotics can be considered ex-
tremely harmful to organisms and high concentrations of an-
tibiotics in sediment inhibit the growth of bacteria (Kümmerer
2009a, b).
The occurrence and diverse effects of some of the highly
ranked APIs have been reported. Although ciprofloxacin, a
fluoroquinolone antibiotic, is highly removed in WWTPs, a
concentration of 3.8 μg L−1 was detected in wastewater efflu-
ent in Australia (Watkinson et al. 2007) and much higher
concentrations of 6.5 and 14.0 mg L−1 from two lakes and
pharmaceutical production effluent in India, respectively
(Fick et al. 2009). Ciprofloxacin showed luminescence inhi-
bition toVibrio fisheri at 5 mg L−1 of 30-min EC50 (Hernando
et al. 2007) and shows high toxicity toward cyanobacteria
(Microcystis aeruginosa) with an EC50 of 0.005 mg L−1 with
growth inhibition as the endpoint (Halling-Sorensen 2000). In
a recent study, ciprofloxacin exposure resulted in growth in-
hibition of algae (Pseudokirchneriella subcapitata) at a 96-h
EC50 of 4.83 mg L−1 (Martins et al. 2012). Erythromycin is
frequently detected in water around the world with concentra-
tions between 0.13 and 0.89 μg L−1 (Meinertz et al. 2011;
Hernando et al. 2006). It was found to be toxic to algae using
chronic tests with a reported EC50 between 0.01 and
0.1 mg L−1 while ecotoxicological results showed that acute
toxicity was in the range of 10–30 mg L−1 for algae, daphnia
and bacteria (Isidori et al. 2005). Clarithromycin, a derivative
of erythromycin, was detected in concentrations between 0.01
and 0.54 μg L−1 in different countries and has been shown to
inhibit the growth of algae and cyanobacteria with EC50
values of 0.0371 and 0.0121 mg L−1, respectively (Baumann
et al. 2014). The PECsw of amoxicillin, a β-lactam antibiotic,
in Iraqi cities was very high and ranged from 0.6 to
24.0 μg L−1. This concentration is extremely high in
comparison to levels <0.001 μg L−1 detected in other coun-
tries such as in Italy (Castiglioni et al. 2004). It shows high
toxicity to blue-green algae (cyanobacteria) with a
reported 96-h EC50 of 0.00222 mg L−1 (Fass.se) and is
known to cause hepatocyte cytotoxicity as side effect to
rainbow trout with a 24-h EC50 >182.7 mg L−1 (Laville
et al. 2004).
In addition to direct toxicological risks, the occurrence of
antibiotics raises concerns in terms of the promotion of anti-
biotic resistance in bacteria in environment, which could sub-
sequently make antibiotics ineffective in terms of treatment
for both humans and animals since aquatic ecosystems are a
recognized reservoir for antibiotic-resistant bacteria (Santos et
al. 2010; Kostich et al. 2014; Ågerstrand et al. 2015).
Interestingly, the occurrence of antibiotic resistance in the en-
vironment is not on the main list of priorities that should be
addressed by guidelines for the environmental risk assessment
of medicinal products for both human and veterinary use in
the European Union [European Medicines Agency (EMEA)
2006; 2008]. Studies from different parts of the world
have highlighted the fact that resistant strains of bacteria
occur in the environment. For example, in Slovakia, the
occurrence of resistance to different antibiotics (erythromycin,
clarithromycin, azithromycin, ciprofloxacin, trimethoprim) in
coliforms and streptococci from WWTPs sludge was studied
(Birošová et al. 2014). In Canada, isolated Escherichia coli
retrieved from different sites and aquatic ecosystem compart-
ments (biofilms, sediment and water) showed high frequency
of resistance to ampicillin and ciprofloxacin (Maal-Bared et
al. 2013). In Brazil, three strains of Salmonella from
water samples of a shrimp farm exhibited multiresistance to
ampicillin, tetracycline, oxytetracycline and nitrofurantoin
(Carvalho et al. 2013). Recently, a study of tetracyclines, sul-
fonamides and (fluoro)quinolones in sediment and water sam-
ples in Guangdong, China, indicated that fish ponds are res-
ervoirs of antimicrobial resistance genes and the presence of
potential resistant and pathogen-associated taxonomic groups
in fish ponds might imply the potential risk to human health
(Xiong et al. 2015).
Two non-steroidal anti-inflammatory drugs (NSAIDs)
were identified as high priority APIs i.e. diclofenac and
mefenamic acid. In 2013, the European Directive identified
diclofenac, alongside two synthetic hormones, as pollutants
that should be included in the Water Framework Directive
Watch List (Carvalho et al. 2015). van den Brandhof and
Montforts (2010) reported the effect of diclofenac on growth
retardation in zebrafish after exposure to concentrations
>1.5 mg L−1. Hoeger et al. (2005) and Schwaiger et al.
(2004) documented that diclofenac has the potential to cause
histopathological damage to tissues (kidney) in fish at concen-
trations close to those regularly found in surface waters.
Mefenamic acid showed a maximum PECsw (1.2 μg L−1)
which is higher than the reported levels (0.20-0.34 μg L−1)
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in the UK by Roberts and Thomas (2006). Ecotoxicological
effect of mefenamic acid in chronic toxicity tests to Daphnia
magna and Moina macrocopa showed significant changes in
reproduction (number of young per adult) after the exposure to
1.0 and 0.25 mg L−1 of mefenamic acid, respectively (Jung
Collard et al. 2013). The top used compound in Iraq is
paracetamol. In our study, the maximum PECsw for
paracetamol in Iraqi cities was 23.99 μg L−1 in Basrah
which is two times higher than the concentration obtain-
ed from a study by Jones et al. (2002) who found the
maximum PEC in English rivers to be 11.96 μg L−1 and
more than two orders of magnitude higher than the con-
centration of 0.11 μg L−1 which was detected in 24 % of
the rivers in the USA (Kolpin et al. 2002). In terms of
ecotoxicological effect, Galus et al. (2013) found that
embryonic mortality of zebrafish was raised after expo-
sure to paracetamol at the level of ≥0.5 μg L−1. Very limited
studies have been performed on ecotoxicity of valproic acid
toward environmental organisms. Herrmann (1993)
carried out a prescreen test to investigate the possible
hazard posed to humans using zebra fish exposure to
valproic acid and revealed that exposure caused retarda-
tion and interruption of development. The cholesterol-
lowering agent atorvastatin was reported to affect lemna
(Lemna gibba) by decreasing pigment content at EC50
0.17 mg L−1 (Brain et al. 2004). It was also found to inhibit
growth of Hyalella azteca with LC50 values ranging from
1.30 to 3.56 mg L−1 and Chironomus tentans with LC50
values ranging from 3.94 to 16.42 mg L−1 (Dussault et al.
2008). Amitriptyline was identified as a high priority list due
to its potential to elicit subtle effect in fish in the current study.
It has previously been reported to pose a risk to surface waters
and show toxicity to fish and daphnia, EC50=0.78 mg L−1
(Kasprzyk-Hordern 2010). In lower trophics, amitriptyline
was reported to inhibit the growth of a macrophyte Lemna
minor with a 7-day EC50 of 1.69 mg L−1 (Ågerstrand and
Rudén 2010).
Ibuprofen is predicted to occur in Iraqi surface water at
concentrations of 0.13–0.8 μg L−1 and sediment at concentra-
tions of 3.0–20 μg Kg−1. The log Kow of 3.73 and low solu-
bility suggest the low mobility of ibuprofen in water and af-
finity to adsorb to sediment (Bouissou-Schurtz et al. 2014).
Ibuprofen was detected at a concentration of 1.3 μg L−1 in
surface water in Switzerland (Tixier et al. 2003) and
0.15–3.96 μg L−1 in the influent and effluent wastewa-
ter in Sweden (Bendz et al. 2005). It was found that
exposure to chronic low levels of ibuprofen alters the
pattern of reproduction of Japanese medaka, Oryzias latipes,
and may produce sex-specific responses in teleosts (Flippin
et al. 2007). Ibuprofen at a concentration slightly higher than
0.2 μg L−1 is able to significantly increase both genetic and
cellular damage in freshwater bivalve Dreissena polymorpha
(Parolini et al. 2011).
Limitation of the method
Knowledge about usage data is essential to establish a priority
list of pharmaceuticals of most concern. In Iraq, it was difficult
to obtain the consumption amount of all pharmaceuticals from
the ministry of health list due to absence of a governmental
statistical data and it is sometimes considered confidential.
Moreover, it was not possible to quantify the usage data of
over-the-counter (OTC) pharmaceuticals. Therefore, an accu-
rate quantification approach of OTC usage should be a future
priority. The project did not consider veterinary pharmaceuti-
cals, but this use pattern could also be an important contributor
to the environment, particularly for antibiotic compounds.
Another restraint which increases the uncertainty is the
limited availability of ecotoxicological endpoints and the high
dependence on the prediction of effects and properties. For
example, the practice of using ECOSAR to extrapolate
ecotoxicity data may not be appropriate since this software
was developed to assess toxicity of compounds other than
pharmaceuticals. Physico-chemical properties were also lim-
ited; for instance, Koc which was used to estimate adsorption
during wastewater treatment was calculated by an empirical
estimation model (Franco and Trapp 2008) due to absence of
experimental values for all the pharmaceuticals on the list.
Moreover, bioconcentration factors for worm (BCFworm)
was predicted according to the TGD 2003 to allow the sec-
ondary poisoning assessment of pharmaceuticals in the terres-
trial compartment due to limited availability of experimental
data. This estimation is usually higher than the experimentally
obtained BCF values (TGD 2003). Therefore, an improve-
ment in the accuracy of BCFworm estimation in soil warrants
further consideration.
Conclusion
An approach has been developed for prioritizing substances
that may pose a risk to the aquatic and terrestrial systems in
Iraq. Pharmaceutical usage data has been used together with
information on the physico-chemical properties, patient me-
tabolism and wastewater treatment removal in this practice to
predict API concentrations. The ranking has been performed
by comparing these concentrations to a range of experimental
and estimated ecotoxicological endpoints including non-
standard endpoints such as the potential for subtle phar-
macological effects, secondary poisoning and the impact
on human via consuming fishery products and drinking
water. Dilution factor was found to play an important
role to reduce the risk suspected to be posed toward
environmental organisms by pharmaceuticals, and results
of this study showed that the release of pharmaceuticals
to the aquatic environment represents a significant envi-
ronmental threat, especially when DF is low.
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Twenty-three APIs including antibiotics, analgesics, anti-
epileptics, anti-hypercholesterolemia and anti-asthma have
been identified as high priority substances. The study indi-
cates that antibiotics are the pharmaceutical class of most con-
cern with annual consumption of these molecules in Iraq up to
420 t year−1. Risks of pharmaceutical compounds in drinking
water to human health are low with the exception of tramadol
when no WWTP connectivity exists. Large numbers of phar-
maceuticals considered in this study could be removed during
wastewater treatment, and their risk towards environment will
be highly reduced when a proper removal mechanism is used,
but in our study case, the removal by this method is neglected
due to the absence or inefficient operation of WWTPs in Iraq.
Further evaluation is recommended to assess whether these
compounds could indeed pose a risk to the environment as
individuals or in a mixture since a broad range of different
substances is used simultaneously in humans in any given
area.
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